What’s Next for Neos Therapeutics Incorporated (NASDAQ:NEOS) After Having More Shares Shorted?

July 18, 2017 - By Marry Poplack

 What's Next for Neos Therapeutics Incorporated (NASDAQ:NEOS) After Having More Shares Shorted?

The stock of Neos Therapeutics Incorporated (NASDAQ:NEOS) registered an increase of 2.57% in short interest. NEOS’s total short interest was 2.87 million shares in July as published by FINRA. Its up 2.57% from 2.80 million shares, reported previously. With 314,900 shares average volume, it will take short sellers 9 days to cover their NEOS’s short positions. The short interest to Neos Therapeutics Incorporated’s float is 24.16%.

The stock decreased 0.71% or $0.05 during the last trading session, reaching $7. About shares traded. Neos Therapeutics Inc (NASDAQ:NEOS) has risen 9.07% since July 18, 2016 and is uptrending. It has underperformed by 7.63% the S&P500.

Neos Therapeutics, Inc. is a pharmaceutical company. The company has market cap of $197.12 million. The Firm is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. It currently has negative earnings. The Company’s segment is engaged in the development, manufacturing and commercialization of pharmaceuticals.

Neos Therapeutics Inc (NASDAQ:NEOS) Ratings Coverage

Among 6 analysts covering Neos Therapeutics (NASDAQ:NEOS), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Neos Therapeutics had 11 analyst reports since August 17, 2015 according to SRatingsIntel. BMO Capital Markets initiated it with “Outperform” rating and $26 target in Monday, August 17 report. The firm has “Buy” rating given on Tuesday, June 20 by BMO Capital Markets. The rating was maintained by RBC Capital Markets with “Outperform” on Thursday, November 12. The stock of Neos Therapeutics Inc (NASDAQ:NEOS) has “Neutral” rating given on Monday, March 20 by UBS. The rating was initiated by JMP Securities with “Market Outperform” on Monday, August 17. The company was initiated on Friday, February 19 by Wells Fargo. The stock has “Outperform” rating by RBC Capital Markets on Monday, August 17. The firm earned “Market Outperform” rating on Wednesday, March 9 by JMP Securities. The rating was initiated by BMO Capital Markets on Wednesday, June 29 with “Outperform”.

More news for Neos Therapeutics Inc (NASDAQ:NEOS) were recently published by: Seekingalpha.com, which released: “Neos Looks Attractive With Short And Long-Term Catalysts” on June 30, 2017. Globenewswire.com‘s article titled: “Neos Therapeutics Announces FDA Approval of Cotempla XR-ODTâ„¢ (methylphenidate …” and published on June 20, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: